Cargando…
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
Progression of aggressive prostate cancers (PCa) with androgen receptor splice variants or neuroendrocrine features is currently untreatable in the clinic. Therefore novel therapies are urgently required. We conducted RNA-seq using tumors from a unique murine transplant mouse model which spontaneous...
Autores principales: | Kirk, Jason S., Schaarschuch, Kevin, Dalimov, Zafardjan, Lasorsa, Elena, Ku, ShengYu, Ramakrishnan, Swathi, Hu, Qiang, Azabdaftari, Gissou, Wang, Jianmin, Pili, Roberto, Ellis, Leigh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413643/ https://www.ncbi.nlm.nih.gov/pubmed/25605014 |
Ejemplares similares
-
Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
por: Ellis, Leigh, et al.
Publicado: (2013) -
Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis
por: Ellis, Leigh, et al.
Publicado: (2014) -
Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014) -
YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
por: Ciamporcero, Eric, et al.
Publicado: (2015) -
Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies
por: Lasorsa, E, et al.
Publicado: (2015)